Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00484536 · ClinicalTrials.gov registry record · Phase 2
Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323
A Phase 2 study, sponsored by UCB Pharma.
- Terminated
- Registry status
- Phase 2
- Development phase
- 232
- Enrollment target
NCT00484536 is a Phase 2 study that was terminated before completion, run by UCB Pharma. The registered enrollment target is 232 participants.
The verdict
NCT00484536, a Phase 2 study, was terminated before completion, sponsored by UCB Pharma.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 232 participants
- Enrollment target
Study Summary
The objective of the study is to evaluate the effect, safety and tolerability of CDP323 in patients with relapsing forms of multiple sclerosis
Interventions
- DRUG placebo
- DRUG CDP323
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 232 participants |
| Start Date | 2007-05 |
| Est. Completion | 2010-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00484536
The ClinicalTrials.gov registry entry for NCT00484536 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 232 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Pharma, which has 100 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00484536 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00484536 about?
NCT00484536 is a clinical study titled "Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323". The objective of the study is to evaluate the effect, safety and tolerability of CDP323 in patients with relapsing forms of multiple sclerosis
What is the current status of trial NCT00484536?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 232 participants. The study started on 2007-05. Estimated completion is 2010-07.
What interventions are being tested in trial NCT00484536?
The interventions under investigation include: placebo (DRUG), CDP323 (DRUG).
Who is sponsoring clinical trial NCT00484536?
This trial is sponsored by UCB Pharma, which has 100 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.